Surrogate and mediating endpoints: current status and future directions

J Natl Cancer Inst. 2009 Feb 18;101(4):216-7. doi: 10.1093/jnci/djn515. Epub 2009 Feb 10.
No abstract available

Publication types

  • Comment
  • Editorial

MeSH terms

  • Biomarkers* / analysis
  • Clinical Trials as Topic / methods*
  • Confidence Intervals
  • Endpoint Determination / methods*
  • Humans
  • Male
  • Odds Ratio
  • Prostatic Neoplasms* / immunology
  • Prostatic Neoplasms* / mortality
  • Prostatic Neoplasms* / pathology
  • Prostatic Neoplasms* / therapy
  • Research Design
  • Treatment Failure

Substances

  • Biomarkers